Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Stuart J. Swiedler, Emil Kakkis et al.|The Journal of Pediatrics|2006Cited by 364
The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentationStefan Kölker, Nicholas J. Thompson, Stephanie Grünewald et al.|Journal of Inherited Metabolic Disease|2015Cited by 248
The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotypeStefan Kölker, Étienne Sokal, Daniela Karall et al.|Journal of Inherited Metabolic Disease|2015Cited by 236
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseMaurizio Scarpa, J. E. Wraith, Gunilla Malm et al.|Orphanet Journal of Rare Diseases|2011Cited by 231
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Celeste Decker, Paige Kaplan et al.|Molecular Genetics and Metabolism|2008Cited by 216